| First Author | Kong A | Year | 2023 |
| Journal | Int Immunopharmacol | Volume | 116 |
| Pages | 109792 | PubMed ID | 36738679 |
| Mgi Jnum | J:334493 | Mgi Id | MGI:7441738 |
| Doi | 10.1016/j.intimp.2023.109792 | Citation | Kong A, et al. (2023) Novel antidepressant-like properties of the fullerenol in an LPS-induced depressive mouse model. Int Immunopharmacol 116:109792 |
| abstractText | Depression is a common mental disease and is highly prevalent in populations. Dysregulated neuroinflammation and concomitant-activated microglia are involved in the pathogenesis of depression. Experimental evidence has indicated that fullerenol exerts anti-neuroinflammation and protective effects against neurological diseases. Here, we evaluated fullerenol's effects against lipopolysaccharide (LPS)-induced mouse depressive-like behaviors. Fullerenol treatment produced an antidepressant-like effect, as indicated by preventing the LPS-induced reduction in the sucrose preference and shortening the immobility durations in both the tail suspension test and the forced swim test. We found that fullerenol treatment mitigated LPS-induced hippocampal microglia activation and released proinflammatory cytokines. Meanwhile, fullerenol promoted hippocampus neurogenesis, evidenced by increased DCX-positive cells in LPS-treated mice. Hippocampal RNA-Seq analysis revealed proinflammatory cytokine and neurogenesis involved in fullerenol's antidepressant-like effects. Our data indicate that fullerenol exerts antidepressant effects, which might be due to beneficial functions in reducing neuroinflammatory processes and promoting neurogenesis in the hippocampus. |
